|
|
Article: Clinic Roundup.
- Article from:
- BIOWORLD Today
- Article date:
- November 3, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
o Affymax, Inc., of Palo Alto, Calif., initiated a clinical trial to evaluate the use of Hematide to treat anemia in chronic kidney disease patients with pure red-cell aplasia. PRCA, a rare autoimmune disorder, occurs when the body produces neutralizing antibodies to recombinant human erythropoietin, thus suppressing the production of red blood cells by the bone marrow. Hematide is a synthetic, peptide-based, erythropoiesis-stimulating agent being evaluated in Phase II trials to treat anemia in patients with CKD and cancer.
o Amicus Therapeutics, of Cranbury, N.J., said the Committee for Orphan Medicinal Products of the European Medicines Agency recommended ...